Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Earnings Data
Report Date
Aug 14, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.21Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 13.47%
|Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and strategic advancements, particularly in the commercialization of TriNav and preparation for nelitolimod partnerships. However, challenges such as a slight decrease in gross margins and a lack of anticipated positive EBITDA in 2025 were noted.Company Guidance
During the first quarter of 2025, TriSalus Life Sciences made significant progress on its strategic priorities, achieving $9.2 million in net sales—a 42% increase over Q1 2024 and an 11% gain over Q4 2024. The company maintained strong market momentum, enhancing its presence in the liver embolization market and expanding its technology into new clinical settings. TriSalus achieved several milestones, including the completion of Phase 1 trials for nelitolimod and the launch of the TriNav Large and TriGuide, which support deeper penetration into liver markets. The company also reported an 84% gross margin and a 44% reduction in R&D expenses compared to Q1 2024. With the issuance of a new HCPCS code, TriSalus doubled the reimbursable use of its technology, leading to broader adoption. Looking ahead, the company anticipates at least 50% revenue growth for 2025 but does not foresee achieving EBITDA or cash flow positivity within the year, as it invests in strategic areas like expanding its commercial resources and developing new clinical applications.Significant Revenue Growth
TriSalus Life Sciences reported $9.2 million in net sales for Q1 2025, a 42% increase compared to Q1 2024, and an 11% sequential gain over Q4 2024.
Successful Completion of Phase 1 Trials for Nelitolimod
Phase 1 trials for nelitolimod were completed, shifting the focus to a partnership strategy, eliminating development expenses, and preserving long-term value.
Increase in Unique Ordering Accounts
In Q1 2025, the number of unique ordering accounts increased by 39% compared to Q1 2024, with 32 new accounts added.
New Reimbursement Code for TriNav
CMS issued a HCPCS code, C8004, which provides coverage for mapping procedures using TriNav, doubling the reimbursable use of the technology.
Strong Financial Position and Fundraising
TriSalus raised approximately $22 million in gross proceeds through a private placement, enhancing its balance sheet and funding further growth.
Improvement in Operating Losses
Operating losses for Q1 2025 totaled $7.3 million, a significant reduction from $11.7 million in Q1 2024, primarily due to increased sales and reduced R&D expenses.
TLSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TLSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $4.90 | $5.11 | +4.29% |
Mar 27, 2025 | $5.58 | $5.50 | -1.43% |
Nov 14, 2024 | $4.50 | $4.01 | -10.89% |
Aug 15, 2024 | $5.85 | $5.89 | +0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TriSalus Life Sciences (TLSI) report earnings?
TriSalus Life Sciences (TLSI) is schdueled to report earning on Aug 14, 2025, TBA Not Confirmed.
What is TriSalus Life Sciences (TLSI) earnings time?
TriSalus Life Sciences (TLSI) earnings time is at Aug 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLSI EPS forecast?
TLSI EPS forecast for the fiscal quarter 2025 (Q2) is -0.21.